Dogwood Therapeutics Bolsa (NASDAQ: DWTX)

Últimas noticias sobre Dogwood Therapeutics (NASDAQ:DWTX) Bolsa

Dogwood Therapeutics

Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics Inc

Fusion Fuel Green Plc ("Fusion Fuel" or the "Company") announced today that it has issued a damages claim against Hydrogenial S.A. ("Hydrogenial" or the "Investor") and its principal, Mr. Norbert Bindner, following their failure to fund the $33.5 million Subscription Agreement disclosed in the Company's Form 6-K on September 11, 2024. Under the terms of this agreement, entered into in good faith by the Company on August 28, 2024, the Investor committed to purchase an aggregate of 43,790,850 Class A ordinary shares (the "Class A Shares"), along with warrants to acquire an additional 13,137,254 Class A Shares, for a total purchase price of $33,500,000.
Pursuant to Section 3 of the Subscription Agreement, the closing was to take place on September 30, 2024, with full payment due at or before the time of the closing. Despite all conditions to closing being met, as confirmed in discussions with Hydrogenial representatives, the Investor failed to fund in a timely fashion. The Company promptly informed Hydrogenial of its breach and requested immediate resolution, and Hydrogenial subsequently provided the Company with a revised closing date of October 25, 2024; however, to date, the Company has yet to receive proceeds from the investment. This continued delay has led Fusion Fuel to pursue legal recourse.
As a direct consequence of the funding delay, Fusion Fuel has filed for insolvency for its Portuguese subsidiary, Fusion Fuel Portugal S.A., out of which the most significant portion of the Company's technology sales and project development activities had been conducted. On the advice of insolvency counsel, the Company has submitted a claim in Portugal for damages incurred due to Hydrogenial's breach. The Company notes that the Investor's obligation under the Subscription Agreement remains in effect notwithstanding the filing of the claim and the insolvency of its Portuguese subsidiary.
In response to these events, Fusion Fuel is actively exploring strategic alternatives to preserve shareholder value, including a potential transaction that management believes could complement the Company's hydrogen business and yield significant synergies. The Company expects to provide further updates in short order.

News

HTOO

Fusion Fuel Issues Damages Claim Against Hydrogenial S.A. For Failure To Fund $33.5M Subscription Agreement; Announces Insolvency Of Portuguese Subsidiary, Fusion Fuel Portugal S.A.; Fusion Fuel Is Actively Exploring Strategic Alternatives To Preserve Shareholder Value, Including A Potential Transaction That Management Believes Could Complement The Company's Hydrogen Business And Yield Significant Synergies

MNOV

MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'

Swedish video game company Embracer Group AB's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/THQQF#OTC">THQQF</a>) latest financial results show a steep drop in sales and increased net losses as the company deals with game delays, staff <a href="https://www.benzinga.com/general/gaming">reductions, and restructuring.</a>
<h3 class="wp-block-heading">Q2 Financial Summary: Declining Sales And Higher Losses</h3>
For the quarter ending Sept. 30, Embracer reported (<a href="https://www.gamesindustry.biz/embracer-pc-and-console-sales-plummet-during-q2">via</a> GamesIndustry.biz) net sales of 8.55 billion SEK (about $774 million), down 21% from the same period last year.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a>
Revenue from PC and console games took the largest hit, falling by 46% year-over-year to 2.12 billion SEK ($192 million), with only a few new releases and mixed reception of existing titles such as Disney Epic Mickey: Rebrushed. 
Mobile games saw an 8% decline, with revenue down to 1.35 billion SEK. The company recorded a net loss of 390 million SEK, a slight improvement from a 562 million SEK loss in the same quarter last year.
<h3 class="wp-block-heading">Six-Month Results: Losses And Reduced Workforce</h3>
Embracer's numbers for the first half of fiscal year 2025 reveal a sharper year-over-year decline. Net sales dropped 23% to 14.4 billion SEK, and its net loss widened to 2.58 billion SEK compared to a 1.69 billion SEK profit last year. 
Workforce reductions reflect the company's major restructuring efforts, with the number of game developers dropping from 10,654 to 6,250, and total headcount falling from 15,701 to 10,450.
<h3 class="wp-block-heading">Game Delays And Studio Divestments</h3>
A significant factor in Embracer's reduced revenues was a lack of major new releases and weaker-than-expected sales of its back catalog. 
Embracer also divested Gearbox and parts of Saber Interactive, affecting its revenue from older titles. CEO Lars Wingefors said, "Parts of our PC/Console and Entertainment &amp; Services segments are still underperforming due to delays and low ROI for primarily small and mid-sized releases." Embracer also recently sold Easybrain to Miniclip in a $1.2 billion deal as part of its efforts to reduce debt and streamline operations.
The company remains focused on core projects with a view toward longer-term growth, notably with the release of Kingdom Come: Deliverance 2, set to launch on Feb. 11, 2025, which Embracer expects will bring strong interest from the gaming community.
<h3 class="wp-block-heading">Outlook: Restructuring And Future Focus</h3>
Embracer anticipates continued lower earnings through the fiscal year, with Wingefors noting that the company has created "a stronger foundation for long-term value creation" by reducing debt and capital expenditures.
Embracer is also moving forward with plans to spin off Asmodee by the fiscal year-end, further refocusing its portfolio around core segments.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41909832/call-of-duty-black-ops-6s-pacifist-player-reaches-prestige-without-any-kills">Call Of Duty: Black Ops 6&#8217;s Pacifist Player Reaches Prestige Without Any Kills</a></li>
</ul>
Image credits: Shutterstock.

Earnings

Gaming

General

THQQF

Embracer's Earnings Struggle As Game Delays, Restructuring Weigh On Results

Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.15) by 33.91 percent. This is a 19.15 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $14.63 million which missed the analyst consensus estimate of $32.22 million by 54.60 percent. This is a 57.90 percent decrease over sales of $34.75 million the same period last year.

Earnings Beats

Earnings Misses

FBIO

Fortress Biotech Q3 EPS $(0.76) Beats $(1.15) Estimate, Sales $14.63M Miss $32.22M Estimate

Operating expenses slashed by 22% year-over-year, falling to $3.9 million from $4.9 million in Q3 2023, reflecting efficiency gains.

WRAP

Wrap Technologies Reports Q3 Revenue Of $593K, Bringing 9-Month Revenue To $3.6M

BM Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#AMEX">BMTX</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.08 million which beat the analyst consensus estimate of $13.62 million by 3.36 percent. This is a 2.11 percent decrease over sales of $14.38 million the same period last year.

BMTX

BM Technologies Q3 Adj $(0.42) Misses $(0.20) Estimate, Sales $14.08M Beat $13.62M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303354-1&amp;h=1786564514&amp;u=http%3A%2F%2Fwww.standex.com%2F&amp;a=Standex+International+Corporation">Standex International Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) today announced that it has acquired Michigan-based Custom Biogenic Systems ("CBS") for approximately $6.2 million in cash. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment.

Standex Acquires Custom Biogenic Systems For ~$6.2M In Cash

Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.01 by 600 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $18.83 million which missed the analyst consensus estimate of $24.00 million by 21.53 percent. This is a 13.75 percent decrease over sales of $21.84 million the same period last year.

GTEC

Greenland Technologies Q3 EPS $(0.05) Misses $0.01 Estimate, Sales $18.83M Miss $24.00M Estimate

Trian Fund Management, the hedge fund led by Nelson Peltz, disclosed substantial portfolio changes in its third-quarter 13F filing, making notable exits from major companies before the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 U.S. presidential election</a>. 
What Happened: The fund sold off its entire stakes in GE HealthCare Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) (1.34 million shares), Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) (2.65 million shares) and Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) (470,000 shares). 
These exits suggest a cautious pivot from sectors like healthcare and entertainment, which face both market challenges and macroeconomic pressures.
Trian also reduced its stakes in several core holdings. The fund cut its position in Wendy&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) by 3%, reducing its shares from 31.5 million to 30.5 million, and scaled down its investment in asset manager Invesco Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) by 15%, from 27.2 million to 23.1 million shares.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
The most substantial reduction came in Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), where Trian slashed its holdings by 69%, to 613,447 shares. These reductions reflect a strategic tightening in sectors affected by recent market volatility and economic uncertainty.
What Else: However, Trian strengthened its position in select companies, raising its stake in Solventum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) from 5.36 million to 7.13 million shares, and held its positions steady in Janus Henderson Group PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) and General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) as its top holdings.
This targeted increase aligns with Trian's confidence in sectors that may benefit from potential industrial and financial sector growth.
Soon after Trian's portfolio moves in the third quarter, Donald Trump's victory in the 2024 U.S. presidential election was confirmed, along with a Republican majority in the Senate.
Trump's policy agenda, which includes corporate tax cuts, increased tariffs and a potential rollback of green energy initiatives, is expected to significantly impact markets. 
Sectors like traditional manufacturing, defense and energy may see gains under Trump's administration, aligning with Trian's portfolio shifts, especially in industrial and financial investments.
Trian's recent moves highlight a forward-looking strategy as the hedge fund prepares for an evolving economic landscape shaped by Trump's return to the White House.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

Politics

GEHC

Janus Henderson Group plc Ordinary Shares

SOLV

Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election

DHAI

DIH Holding US Q2 EPS $(0.01) Up From $(0.10) YoY, Sales $18.2M Up From $13.1M YoY

Fundamental Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) reported quarterly earnings of $15.06 per share. This is a 288.01 percent increase over losses of $(8.01) per share from the same period last year. The company reported $10.45 million in sales this quarter. This is a 155.82 percent increase over sales of $4.09 million the same period last year.

Fundamental Global Q3 EPS $15.06 Up From $(8.01) YoY, Sales $10.45M Up From $4.09M YoY

flyExclusive (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#AMEX">FLYX</a>) reported quarterly losses of $(0.32) per share. The company reported $76.92 million in sales this quarter. This is a 24.02 percent increase over sales of $62.03 million the same period last year.

FLYX

flyExclusive Q3 EPS $(0.32), Sales $76.92M Up From $62.03M YoY

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $7 price target.

Price Target

Analyst Ratings

PASG

Chardan Capital Maintains Buy on Passage Bio, Maintains $7 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

CDXS

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) reported quarterly losses of $(1.54) per share which beat the analyst consensus estimate of $(4.14) by 62.8 percent.

PHIO

Phio Pharma Q3 2024 GAAP EPS $(1.54) May Not Be Comparable To $(4.14) Estimate

Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

AIEV

Thunder Power Holdings Q3 EPS $(0.02), Same YoY

Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(0.94) by 104.26 percent. This is a 139.51 percent decrease over earnings of $4.86 per share from the same period last year.

ATXI

Avenue Therapeutics Q3 EPS $(1.92) Misses $(0.94) Estimate

Legal

GREE

Greenidge Says New York Supreme Court Judge Rejected Department Of Environmental Conservation's Action To Deny Its Application For Renewal Of Title V Air Permit

Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.80) by 5 percent. This is a 14.61 percent increase over losses of $(0.89) per share from the same period last year.

AQMS

Aqua Metals Q3 EPS $(0.76) Beats $(0.80) Estimate

President-elect Donald Trump's nomination of former Democratic Congresswoman <a href="https://www.benzinga.com/topic/tulsi-gabbard">Tulsi Gabbard</a> as Director of National Intelligence (DNI) has sparked debate.
The selection drew mixed reactions due to her unconventional political background and history of controversial statements. Though, the <a href="https://www.benzinga.com/markets/cannabis/23/02/30743988/breaking-the-chains-of-cannabis-criminalization-tulsi-gabbards-fight-for-legalization-from-grine">cannabis industry isn&#8217;t complaining.</a>
If confirmed, Gabbard would become the highest-ranking intelligence official despite a lack of experience within the intelligence community. Her appointment marks a sharp departure from past presidential selections, as she has never served on a congressional intelligence committee.
A former Hawaii Army National Guard member who deployed to Iraq with a medical unit, Gabbard has frequently criticized U.S. foreign policy as overly aggressive and imperialistic. 
Her outspoken stances, including opposition to mainstream U.S. intelligence views on Russia, raise questions about how she will navigate her role overseeing the nation's 18 intelligence agencies with a combined budget of approximately $70 billion.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41982165/new-gop-senate-leader-john-thune-opposes-marijuana-legalization-implications-for-banking-access-and-more">New GOP Senate Leader John Thune Opposes Marijuana Legalization: Implications For Banking Access And More</a>
<h3 class="wp-block-heading">Cannabis Policy Contributions</h3>
Beyond foreign policy, Gabbard's legislative record includes notable contributions to cannabis reform, earning her broad support within the marijuana industry and advocacy groups. Over her eight years in Congress, she was as a vocal supporter of marijuana and hemp reform, introducing legislation that reflected her commitment to decriminalization and medicinal use.
In 2017, Gabbard introduced a bipartisan bill that sought to end federal prohibition by removing cannabis from the Controlled Substances Act, a landmark move that appealed to both sides of the aisle.
"Our archaic and outdated marijuana laws are turning everyday Americans into criminals," Gabbard <a href="https://norml.org/blog/2019/03/07/rep-tulsi-gabbard-i-just-introduced-legislation-to-end-the-federal-marijuana-prohibition/">said</a> at the time. "Every day, the economic and social impacts of marijuana prohibition are having devastating effects on communities across the country." 
Her advocacy extended to military service members. In 2020, she <a href="https://www.benzinga.com/markets/cannabis/20/07/16709095/congress-allows-troops-to-use-cbd-products-1">filed an amendment</a> to permit the use of hemp-derived CBD products, pushing back against the expanding ban on these products within the armed forces and Veterans Administration (VA).
<h3 class="wp-block-heading">Russia Propagandist? </h3>
Despite her legislative achievements and progressive stance on cannabis reform, Gabbard's alignment with the intelligence community's stance on Russia remains contentious. In recent years, she faced backlash from lawmakers who accused her of amplifying Russian propaganda after she shared a video referencing alleged U.S.-funded "bio labs" in Ukraine. The claim was widely debunked by U.S., Ukrainian officials and independent sources.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There are 25+ US-funded biolabs in Ukraine which if breached would release &amp; spread deadly pathogens to US/world. We must take action now to prevent disaster. US/Russia/Ukraine/NATO/UN/EU must implement a ceasefire now around these labs until they're secured &amp; pathogens destroyed <a href="https://t.co/dhDTH5smIG">pic.twitter.com/dhDTH5smIG</a>
&mdash; Tulsi Gabbard &#x1f33a; (@TulsiGabbard) <a href="https://twitter.com/TulsiGabbard/status/1502960938147729413?ref_src=twsrc%5Etfw">March 13, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41992074/trump-says-his-secretary-of-state-pick-marco-rubio-is-powerful-voice-for-freedom-but-what-about-cannabis">Trump Says His Secretary Of State Pick Marco Rubio Is &#8216;Powerful Voice For Freedom&#8217; – But What About Cannabis?</a></li>
</ul>
Photo: <a href="https://www.flickr.com/people/22007612@N05">Gage Skidmore</a>, <a href="https://en.wikipedia.org/wiki/en:Creative_Commons">Creative Commons</a>&nbsp;<a href="https://creativecommons.org/licenses/by-sa/2.0/deed.en">Attribution-Share Alike 2.0</a>/Wikipedia

Cannabis

Government

Trump's National Intelligence Pick Is Cannabis Advocate Tulsi Gabbard: Critics Say Former Congresswoman Parrots Russia Propaganda

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), retaining the price target of $25.0...

Strategic Merger Positions Dogwood Therapeutics for Success with Promising Pipeline and Financial Stability

Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule

Dogwood (DWTX) Therapeutics has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The ...

Dogwood regains compliance with Nasdaq listing rule

Virios Therapeutics GAAP EPS of -$2.05

Virios Therapeutics, Inc. ( ($DWTX) ) has released its Q3 earnings. Here is a breakdown of the information Virios Therapeutics, Inc. presented to i...

Dogwood Therapeutics Reports Q3 2024 Financial Results

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Dogwood Therapeutics (DWTX – Research Report), with a pr...

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

Dogwood Therapeutics Inc (DWTX) has disclosed a new risk, in the Debt & Financing category. Dogwood Therapeutics Inc. faces a significant risk with...

Comments

Dogwood Therapeutics

Noticias

Últimas noticias sobre Dogwood Therapeutics (NASDAQ:DWTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL